SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 18.06-1.2%Jan 27 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: erickerickson who wrote (46213)5/23/2018 12:06:06 PM
From: EagleRare2 Recommendations

Recommended By
ladyPI
moverman

  Read Replies (1) of 53770
 
The business plan can not be underestimated. IMMU is trying to build itself up as a standalone biopharmaceutical company. If you see how the management is executing (i.e. focus on IMMU-132 for AA, establishment of manufacturing, initiating the Phase III, hiring the extensive sales staff, submitting the BLA, securing ample financing through the royalty agreement, hiring effective and accomplished management), then you understand the room for growth in ones investment is great.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext